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Introduction
The V198M mutation is described as a possible hypo-
morphic variant of the NLPR3 gene. However the impact
of this mutation is still largely unknown.
Objectives
To analyse the prevalence of V198M mutation in patients
with a clinical history suggestive for CAPS and to describe
the clinical and laboratory findings of patients carrying
this mutation.
Methods
From 2002 the molecular analysis of the NPLR3 gene was
performed in 524 patients with a clinical history suggestive
for CAPS. In order to estimate the pravalence of the muta-
tion of this gene in the healty population 98 healthy indivi-
duals were also analyzed for the same mutation.
Results
The V198M mutation was found in 13 screened patients:
10 were heterozygous for the mutation only. In one
patient with a typical MWS phenotype the V198M variant
was associated with the Q703K and the D303N mutation
of the same gene. In a patient a low-penetrance mutation
of TNFRSF1A gene (P46L) was also found, while another
one carried the A91V mutation of Pfr1 gene.
Out of the 10 patients heterozygous for the V198M
mutation, five displayed a story of periodic fever associated
with urticarial rash, arthralgia and transient arthritis,
associated with elevation of acute phase reactants and
responding to steroid treatment on demand or to treat-
ment with IL-1 blockers. In two patients the clinical
picture was mild and uniquely characterized by urticarial
rash and arthralgia, often induced by cold, but not asso-
ciated with elevation of acute phase reactants. The other
three patients presented episodes of fever with an incon-
stant elevation of acute phase reactants and not associated
to other symptoms suggestive of CAPS; however one of
this patients developed renal amiloidosis. The patients
carrying the P46L mutation of TNFRSF1A gene presented
periodic fever with athralgia and headache, not associated
with elevation of acute phase reactants. The patient carry-
ing the A91V mutation of Pfr1 gene presented some clini-
cal characteristics suggestive of CINCA syndrome
associated to not typical ones; this patient died at the age
of 4.7 years with a clinical pictures consistent of MAS.
3 patients were treated with IL-1 blockers (anakinra at
the staring dosage of 1 mg/kg and canakinumab at the
starting dosage of 2 mg/kg every 8 weeks), two heterozy-
gous for V198M and one compound heterozygous for
V198M, D303D and Q703 K, with a rapid a complete con-
trol of the clinical manifestations.
None of the healthy individuals screened for the V198M
mutation turned out to be positive.
Conclusion
This study confirms the low-penetrance of the V198M
mutation of the NLPR3 gene. However a minority of these
patients may present a clinical phenotype consisting with
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